Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,397 shares of the biopharmaceutical company’s stock after selling 399 shares during the period. Exchange Traded Concepts LLC’s holdings in Halozyme Therapeutics were worth $115,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Janney Montgomery Scott LLC grew its stake in Halozyme Therapeutics by 698.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after purchasing an additional 251,711 shares in the last quarter. Sugar Maple Asset Management LLC acquired a new position in shares of Halozyme Therapeutics during the fourth quarter worth about $373,000. Diversify Advisory Services LLC grew its position in shares of Halozyme Therapeutics by 9.3% during the fourth quarter. Diversify Advisory Services LLC now owns 5,825 shares of the biopharmaceutical company’s stock worth $308,000 after buying an additional 494 shares in the last quarter. Diversify Wealth Management LLC increased its stake in shares of Halozyme Therapeutics by 63.8% during the fourth quarter. Diversify Wealth Management LLC now owns 15,464 shares of the biopharmaceutical company’s stock worth $816,000 after buying an additional 6,025 shares during the period. Finally, Empirical Asset Management LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $1,091,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 0.4 %

HALO stock opened at $56.64 on Friday. The company has a market cap of $7.21 billion, a price-to-earnings ratio of 18.76, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24. The company has a fifty day moving average price of $50.65 and a 200 day moving average price of $54.32. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of recent analyst reports. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Piper Sandler increased their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.